Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Hit Repeat

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Apr 18, 2024 8:58am

75 Views

Post# 35995503

RE:RE:RE:RE:RE:RE:RE:RE:RE:Hit Repeat

Azzak.....way to out the absolute blatant hypocracy of ENEMEMENE and his feigned concern of cancer patients over on the Medicenna board while posting here, trashing the 3x better results of Pelareorep in Oncy's trials....X13245623 (or whatever meaningless monicker he uses) is also over there singing Medicenna's praises while spreading lies here about the incredible successes the Oncy team has achieved.

<< Previous

Bullboard Posts

Next >>

Mining companies take action on reconciliation with First Nations